1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Straumann Holding AG

Straumann Holding AG

0QMV.IL
Straumann Holding AGGB flagInternational Order Book
99.79
CHF
-0.71
- -
15.91BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
4.4
4.57
5.1
5.87
7.18
8.62
10.07
8.98
12.71
14.57
14.28
- -
- -
Basic EPS, GAAP
0.65
1.01
0.45
1.47
1.8
1.72
1.93
0.57
2.49
2.73
1.54
- -
- -
Free Cash Flow per Basic Share
0.9
0.82
0.96
0.88
0.93
1.06
1.44
1.85
2.76
1.38
1.99
- -
- -
Dividend per Share
0.37
0.37
0.37
0.4
0.42
0.47
0.52
0.57
0.57
0.67
0.8
- -
- -
Book Value per Share
4.06
4.72
3.85
4.13
6.81
7.58
8.59
7.58
9.4
11.62
11.52
12.79
13.55
Tangible Book Value per Share
3.6
4.28
2.28
2.09
2.72
3.46
3.91
3.49
5.38
6.74
5.82
7.13
8.08
Basic Weighted Avg Shares
155
156
157
156
155
158
159
159
159
159
159
- -
- -
Sales/Revenue/Turnover
680
710
799
918
1,112
1,364
1,596
1,426
2,022
2,321
2,277
2,504
2,605
Operating Margin (%)
16.62
20.57
21.34
24.5
25.17
24.88
23.45
10.64
26.53
23.07
26.27
24
21.08
Depreciation Expense
32
28
35
32
40
52
93
99
103
163
123
145
158
Net Income, GAAP
101
158
71
230
280
273
306
91
396
435
246
388
356
Effective Tax Rate (%)
15.59
11.05
10.83
- -
12.65
14.9
15.72
19
16.36
12.77
17.98
17.89
21.33
Profit Margin (%)
14.88
22.22
8.85
25.02
25.14
20
19.2
6.4
19.59
18.73
10.81
15.51
13.66
Working Capital
443
526
386
289
471
491
303
773
966
621
676
579
903
LT Debt
199
199
200
200
201
201
232
696
681
395
383
185
397
Total Equity
631
737
605
634
1,077
1,204
1,367
1,210
1,500
1,854
1,839
2,044
2,165
Return on Invested Capital (%)
13.08
14.42
17.02
- -
22.48
20.77
18.75
6.31
20.9
18.76
19.47
20.09
16.61
Return on Capital (%)
14.57
18.3
8.48
- -
26.71
20.5
19.81
5.48
19.67
18.89
10.72
17.17
14.54
Return on Common Equity (%)
16.41
23.07
10.53
37.07
32.68
23.95
23.9
7.11
29.34
25.98
13.35
20.04
16.95

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.24%
12.76%
5.92%
Free Cash Flow
10.96%
6.37%
-11.12%
Net Income, GAAP
53.61%
69.95%
-8.34%
Sales/Revenue/Turnover
13.38%
13.74%
4.05%
Total Cash Common Dividend
10.11%
10.87%
11.75%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2,277
2024
- -
- -
- -
- -
2,504
2025
- -
- -
- -
- -
2,605

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.54
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.8
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Guillaume Daniellot
Full Time Employees
11,824
Sector
Healthcare
Industry
Medical - Specialties
Address
Peter Merian-Weg 12 Basel BS Switzerland 4002
IPO Date
Oct 6, 2014
Website
straumann.com
Similar Companies
STERIS plc (STE)
SpectraScience, Inc. (SCIE)
Molbio Diagnostics Limited (MOLBIO.BO)
Access Bio, Inc. (950130.KQ)
Avitar, Inc. (AVTI)
Sincere Co. Ltd. (7782.T)
Business
Straumann Holding AG engages in the development, manufacture, and distribution of dental implants, biomaterials, and digital dentistry solutions. Its core products and services encompass dental implants; restorative and esthetic components; prosthetic systems; zirconia and ceramic implants; regenerative biomaterials and bone graft substitutes; digital dentistry platforms, software and guidance systems; patient-specific surgical solutions; and related accessories and monitoring products. The company operates across design, manufacturing, marketing, and service of dental restoration and implant systems, including guided surgery, prosthetics, and maintenance services. Latest major company changes include strategic partnerships and acquisitions to expand digital dentistry capabilities and premium implant products; launches of new implant systems and regenerative biomaterials; expansion of distribution and service networks; and organizational refinements to enhance global commercial execution and regional resilience. Recent funding rounds or corporate transactions reinforce investment in R&D, manufacturing scale, and digital workflow integration; notable partnerships/alliances emphasize interoperability with dental practices, labs, and software providers; and several product introductions broaden the company’s portfolio in high-end implantology and biomaterials. Industry, segments, and markets: dental implants, regenerative biomaterials, prosthetic components, digital dentistry, and related services; serves dental practitioners, laboratories, clinics, and distributors; targets global markets in Europe, North America, Asia-Pacific, and emerging regions; subsidiaries and regional entities support regional manufacturing, sales, and service delivery; parent company relationships align Straumann with a diversified dental solutions ecosystem. Founding year and headquarters location are specified on corporate materials; headquarters are located in Switzerland.